The Metabolic Syndrome and Risk of Chronic Kidney Disease: Pathophysiology and Intervention Strategies by LaGuardia, Heather A. et al.
Hindawi Publishing Corporation
Journal of Nutrition and Metabolism
Volume 2012, Article ID 652608, 9 pages
doi:10.1155/2012/652608
Review Article
TheMetabolic Syndromeand RiskofChronicKidneyDisease:
Pathophysiology and Intervention Strategies
Heather A. LaGuardia,1 L.Lee Hamm,1 andJing Chen2
1Tulane University, New Orleans, LA 70112, USA
2Tulane School of Medicine, Tulane University 1430 Tulane Avenue, SL-45, New Orleans, LA 70112, USA
Correspondence should be addressed to Jing Chen, jchen@tulane.edu
Received 16 June 2011; Revised 14 December 2011; Accepted 14 December 2011
Academic Editor: Andr´ ea Name Colado Sim˜ ao
Copyright © 2012 Heather A. LaGuardia et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Metabolic syndrome is characterized by a clustering of cardiovascular risk factors, including abdominal obesity, elevated blood
pressure and glucose concentrations, and dyslipidemia. The presence of this clinical entity is becoming more pervasive throughout
the globe as the prevalence of obesity increases worldwide. Moreover, there is increased recognition of the complications and
mortality related to this syndrome. This paper looks to examine the link between metabolic syndrome and the development of
chronic kidney disease.
1.Introduction
Metabolic syndrome refers to a cluster of metabolic abnor-
malities (abdominal obesity, hyperglycemia, dyslipidemia,
and hypertension) related to a state of insulin resistance,
often associated with an overweight or obese state. This
clinical entity has been known to increase the risk of car-
diovascular disease (CVD), type 2 diabetes, chronic kidney
disease (CKD), and total mortality.
Metabolic syndrome is highly prevalent worldwide, with
aprevalencerangingfrom10to40%indiﬀerentpopulations
[1–3]. Recently emerging data have suggested that metabolic
syndrome is an important risk factor for CKD. CKD is
a major risk factor for CVD and premature death [4–7].
Better understanding of the underlying pathophysiology of
metabolic syndrome related to CKD will help to identify
potential treatment strategies to reduce CKD risk. The pur-
pose of this paper is to explore the potential pathophysiology
and treatment strategies related to metabolic syndrome and
CKD by integrating available data from the literature.
2.Deﬁnition of Metabolic Syndrome
In 1923, Kylin [8] ﬁrst described a constellation of metabolic
disturbancesthatincludedhypertension,hyperglycemia,and
hyperuricemia. Later scientists noted that, when these syn-
dromes clustered together, they could have disastrous health
consequences and referred to the clustering as syndrome X,
insulin resistance syndrome, the deadly quartet, and obesity
dyslipidemia syndrome [9–13]. Between 1998 and 2005,
three deﬁnitions of metabolic syndrome had been developed
and widely used (Table 1). The three deﬁnitions stated that
the primary components of the syndrome included central
obesity, dyslipidemia, elevated blood pressure, and increased
glucose. Furthermore, previous studies have reported that
all three deﬁnitions will identify persons at increased risk
for diabetes, cardiovascular disease, and all-cause mortality
[3, 14–16]. However, it is noteworthy that the NCEP ATP
III deﬁnition was a more powerful predictor of CVD and
diabetes than the IDF deﬁnition [17–20], while the IDF
deﬁnition identiﬁed more patients than the NCEP ATP III
deﬁnition [19, 21] according to recent studies. Therefore,
NCEP ATP III deﬁnition may have had more clinical impact.
In 2009, a global deﬁnition was developed by multiple orga-
nizations including the International Diabetes Federation
(IDF), National Heart, Lung, and Blood Institute (NHLBI),
the World Heart Federation, the International Atheroscle-
rosis Society, and the American Heart Association (AHA)
in an eﬀort to harmonize clinical diagnosis of metabolic
syndrome. Their deﬁnition, summarized in Table 2, is the2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1
Parameters WHO (1998) NCEP ATP3 (2001) IDF (2005)
Required Insulin resistance in the top
25%; glucose Waist >94cm (men) or 80cm (women)
Number of abnormalities >2 >3 >2
Glucose
>6.1mmol/L (110mg/dL);
2-hour glucose
>7.8mmol/L (140mg/dL)
>5.6mmol/L (100mg/dL)
or drug treatment for
elevated blood glucose
>5.6mmol/L or diagnosed diabetes
HDL cholesterol
<0.9mmol/L (35mg/dL)
(men); <1.0mmol/L
(40mg/dL) (women)
<1.0mmol/L men
(40mg/dL) (men);
<1.3mmol/L (50mg/dL)
(women) or drug treatment
for low HDL-C
<1.0mmol/L (40mg/dL) (men); <1.3mmol/L
( 5 0m g / d L )( w o m e n )o rd r u gt r e a t m e n tf o rl o w
HDL-C
Triglycerides ≥1.7mmol/L (150 mg/dL)
≥1.7mmol/L (150mg/dL)
or drug treatment for
elevated triglycerides
≥1.7mmol/L (150mg/dL) or drug treatment for
elevated triglycerides
Obesity
Waist/hip ratio >0.9 (men)
or >0.85 (women) or BMI
≥30kg/m2
Waist ≥102cm (men) or
≥88cm (women) Waist ≥94cm (men) or ≥80cm (women)
Hypertension ≥140/90mmHg
≥130/85mmHg or drug
treatment for HTN
≥130/85mmHg or drug treatment for HTN
Table 2
Measure Categorical cut points
Elevated waist circumference Population- and country-speciﬁc deﬁnitions
Elevated triglycerides or drug treatment for elevated triglycerides ≥150mg/dL
Reduced HDL-C or drug treatment for reduced HDL-C <40mg/dL in men, <50mg/dL in women
Elevated blood pressure or antihypertensive drug treatment Systolic ≥130mmHg and/or diastolic ≥85mmHg
Elevated fasting glucose or drug treatment of elevated glucose ≥100mg/dL
Adapted from [22].
same as that by NCEP ATP III with an exception that
the criteria for elevated waist circumference are based on
population- and country- speciﬁc deﬁnitions [22].
3. MetabolicSyndrome and Risk of
ChronicKidney Disease
In the Last ten years, new research has examined the link
between kidney disease and metabolic syndrome. In 2004,
Chen et al. [23] showed that metabolic syndrome was
an independent risk factor of CKD. They examined the
association of metabolic syndrome and risk of CKD in over
6000 subjects who participated in the Third National Health
and Nutrition Examination Survey (NHANES III) and
documented that metabolic syndrome was independently
associated with risk of CKD. In 2005, Kurella et al. [24]
went further to include all metabolic syndrome traits in
relation to risk for CKD. Using data from the ARIC study,
a prospective longitudinal study of CV disease risk factors in
10,096 middle-aged nondiabetic adults, they found that over
a nine-year time span metabolic syndrome increased the risk
of developing chronic kidney disease by approximately 50%.
The multivariable-adjusted odds ratio of developing CKD in
thosewithmetabolicsyndromewas1.43(95%CI1.18–1.73).
They also looked at the individual traits associated with the
syndrome and found that compared with an adult who has
no metabolic syndrome traits, risk for CKD in someone
with all ﬁve of the traits is two and a half times higher. In
2006, Ninomiya et al. examined the relationship between
metabolic syndrome and CKD [25]. They performed a slope
analysis of the association between the glomerular ﬁltration
rate (GFR) slope and metabolic syndrome by using a
multipleregressionmodel.GFRdecreasedsigniﬁcantlyfaster
in patients with 4 or more metabolic syndrome components
compared with those who had 1 or no components. In 2007,
Tozawa et al. [26]c o n d u c t e dap r o s p e c t i v es t u d yt oe x a m i n e
metabolic syndrome as a risk factor for CKD in an Asian
population. They examined CKD in 6,371 subjects without
CKD or diabetes mellitus at baseline from 1997 through
2002 in Okinawa, Japan. During the 5-year followup, 369
(5.7%) participants developed CKD. After adjusting for age,
sex,currentcigarettesmoking,andalcoholdrinkinghabitsat
baseline, the relative risk of developing CKD was 1.86 (95%
conﬁdence interval: 1.43–2.41, P<0.0001) in subjects with
metabolic syndrome.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
4.Pathophysiology ofMetabolic
Syndrome which Predisposes to CKD
4.1. Insulin Resistance. Insulin resistance has been consid-
ered an important pathophysiological factor for metabolic
syndrome [27]. Insulin resistance has traditionally been
deﬁned by defective insulin action resulting in fasting
hyperinsulinemia. Yet, even before fasting hyperinsuline-
mia develops, postprandial hyperinsulinemia exists. The
resultant hyperinsulinemia stimulates glucose uptake by
muscle and suppresses endogenous glucose production in
the liver. In insulin-resistant conditions, the ability of insulin
to augment glucose uptake and inhibit hepatic glucose
production is impaired. This creates a state of hyperglycemia
that stimulates beta cells to secrete large amounts of insulin
postprandially. High insulin concentration may overstimu-
late the cells of the arterial wall in the skeletal muscle.
Binding of insulin to the insulin receptor normally
leads to activation of its tyrosine kinase activity and
autophosphorylation of speciﬁc tyrosine residues of the
receptor. The activated insulin receptor phosphorylates
tyrosine residues on substrate proteins initiating a signaling
cascade. The two major pathways for insulin signaling are
the phosphatidylinositol-3 kinase (PI-3K) and the mitogen-
activated protein (MAP) kinase pathways [28]. The PI-
3K pathway is initiated by tyrosine phosphorylation of a
member of the insulin receptor substrate family, which
is associated with the p85 regulatory subunit leading to
activation of the enzyme. PI-3K causes phosphatidylinos-
itol 3,4,5-phosphate (PIP3) to be produced. This results
in activation of Akt and downstream eﬀector molecules
that mediate metabolic response to insulin. This includes
translocation of the glucose transporter type 4 (GLUT4)
into the membrane. The MAP kinase pathway begins with
phosphorylation of insulin receptor substrate, which binds
Grb2 and activates Ras. Ras then binds and disinhibits Raf,
which activates MEK1 kinase. MEK1 activates extracellular
signal-regulated kinases ERK1 and ERK2. The ERKs mediate
the mitogenic and proinﬂammatory responses of insulin
signaling. In metabolic syndrome and type 2 diabetes, the
pathways leading to activation of PI-3K are blocked, possibly
through serine phosphorylation of the insulin receptor,
leavingtheMAPkinasepathwayopen.TheactivationofERK
MAPK pathway stimulates smooth muscle cell growth and
proliferation, which maintains normal sensitivity to insulin
even in insulin-resistant conditions. The overall eﬀect may
be to enhance atherogenesis.
Another key feature of metabolic syndrome is that
free fatty acid production and release from adipocytes are
not suppressed normally with the usual levels of insulin.
Adipocyte resistance to the antilipolytic eﬀect of insulin and
theconsequentelevatedplasmafreefattyacidlevelsmayplay
an important role in the development of insulin resistance
in muscle and other target tissues. Furthermore, excess fatty
acid blocks the PI-3K signaling pathway. Impairment in
the PI-3K pathway could contribute to vascular endothelial
dysfunction due to decreased nitric oxide [27–29].
Kubo et al. examined the eﬀect of hyperinsulinemia on
renal function in a general Japanese population [30]. The
study examined 2446 residents of a town in Japan age 40–
79 without renal failure and had them undergo a series of
physical and laboratory analyses including glucose tolerance
test.Theresultswereinterpretedthroughcorrelationanalysis
and showed serum insulin, blood pressure, total cholesterol,
low-density lipoprotein cholesterol, triglycerides, and body
mass index were all negatively correlated with the reciprocal
of serum creatinine level. In multiple regression analysis,
the correlation between the sum of insulin levels and the
reciprocalofserumcreatinineremainedsigniﬁcantevenafter
controlling for age, sex, body mass index, blood pressure,
total cholesterol, high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, triglycerides, alcohol intake,
and smoking habits. This study suggested that hyperinsu-
linemia was a signiﬁcant relevant factor of renal function
in the general population. Renal dysfunction from insulin
resistance and hyperglycemia is thought to be associated
with the activation of the renin-angiotensin system (RAS)
leading to elevated angiotensin II and aldosterone levels.
The elevation aﬀects the insulin/insulin-like growth factor-
1 signaling pathways, causing oxidative stress leading to
endothelial disruption, and even the development of CVD
[31]. Insulin resistance and hyperinsulinemia are associated
with decreased endothelial production of nitric oxide and
increased oxidative stress which have been also implicated in
the progression of diabetic nephropathy [32].
4.2. Obesity and Waist Circumference. Visceral adipose tissue
is the abdominal fat of the mesentery and omentum. When
free fatty acids are released from the visceral fat, they
drain into the portal circulation. It has been postulated
that increases in this type of fat are directly associated with
increases in risk for the sequel of metabolic syndrome [33].
In addition, increases in abdominal subcutaneous fat would
release lipolysis products into the systemic circulation and
avoid direct eﬀects on hepatic metabolism (i.e., glucose
production, lipid synthesis, and secretion of prothrombotic
proteins such as ﬁbrinogen and plasminogen activator
inhibitor 1) [34]. Furthermore, human adipocytes produce
an as yet unidentiﬁed mineralocorticoid-releasing factor
that stimulates adrenal aldosterone production by means of
paracrine or endocrine mechanisms [35, 36]. Elevated levels
of aldosterone promote insulin resistance and hypertension
and therefore the development of the metabolic syndrome
[37].
When biopsies of obese patients are examined, focal
and segmental glomerulosclerosis and glomerulomegaly are
the most common morphological renal lesions [38]. Early
changes noted upon review of biopsies seen in nondiabetic
patients with only mild metabolic abnormalities and mild
hypertension include increased glomerular cell proliferation,
increased mesangial matrix, thicker basement membrane,
and increased expression of glomerular transforming growth
factor-beta [39]. The mechanisms of obesity-induced renal
injury likely result from a combination of hemodynamic
and metabolic abnormalities. Many factors contribute to
the increase in both glomerular ﬁltration rate (GFR) and
rise in renal plasma ﬂow (RPF) observed in obese patients.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Insulin resistance likely causes an increase in the eﬀer-
ent arteriolar pressure due to decrease of noradrenaline-
inducedeﬀerentarteriolarconstrictionbyinsulin.Therefore,
the transcapillary pressure gradient increases resulting in
hyperﬁltration [40]. Insulin also stimulates the synthesis of
IGF-1 and IGF-2, both promoting glomerular hypertrophy
[38]. In 2011, Mathew et al. proposed that circulating
cytokines (leptin, adiponectin) and inﬂammatory markers
produced by adipose tissue are directly aﬀecting cells in
the renal glomeruli [28]. Moreover, elevated aldosterone in
obesity promotes ﬁbrosis and target-organ dysfunction by
stimulating plasminogen activator inhibitor, transforming
growth factor β1, and reactive oxygen species (ROS) [41–
43]. Aldosterone also promotes loss of glomerular podocytes
and a consequent decrease in the slit-pore membrane
integrity, with consequent proteinuria [44–47]. In addi-
tion, aldosterone increases renal tubular and interstitial
oxidative stress and inﬂammation, processes that promote
salt-induced tubuloglomerular injury, by means of rapid
nongenomic eﬀects [28].
4.3. Dyslipidemia. This condition is characterized by an
increase in elevated triglycerides (and increased VLDL
particle number), increased small LDL particles, and low
HDL cholesterol. Increased numbers of VLDL and LDL
particles lead to an increased level of total apo-B usually
observed with atherogenic dyslipidemia. Additionally, small
triglyceride-rich lipoproteins have also been found to be
atherogenic [48]. The LDL particles associated with the
metabolic syndrome and atherogenic dyslipidemia tend to
be small and dense. Smaller LDLs have been postulated to
penetrate more easily into the arterial wall as well as be more
prone to atherogenic modiﬁcation [49]. Low HDL is a risk
predictor for the atherogenic process.
Dyslipidemia seen in metabolic syndrome is postu-
lated to cause CKD by inﬂammation and increased oxida-
tive stress, which would cause endothelial damage and
atherosclerosis diseases [50–52]. Manttari et al. used meta-
analysis to postulate that elevated triglycerides and low HDL
cholesterol in the plasma are independent risk factors for the
development of chronic kidney disease [53]. Additionally,
Muntner et al. [54] noted in the ARIC study that high
triglycerides and low HDL cholesterol in plasma signiﬁcantly
increased the probability of developing renal dysfunction. It
has even been examined that use of statins may slow the
progression of chronic kidney disease [55].
4.4. Elevated Blood Pressure. Obese persons have a higher
prevalence of elevated blood pressure than lean persons.
Moreover, a higher blood pressure is a strong risk factor
forcardiovasculardisease[56].Well-knowncomplicationsof
hypertension are CHD, stroke, left ventricular hypertrophy,
heart failure, and chronic renal failure. The relation between
insulin resistance and hypertension is well established [57].
Insulin is a vasodilator when given intravenously to people
who are not obese [58]. In the setting of insulin resistance,
the vasodilatory eﬀect of insulin can be lost [59], but the
renal eﬀect on sodium reabsorption preserved. Metabolic
syndrome is also implicated in salt-sensitive hypertension.
The enhanced insulin resistance in CKD may increase
sodium reabsorption by hyperinsulinemia. This results in
sodium retention and salt-sensitive hypertension. In addi-
t i o n ,F u j i t a[ 60] noted that, in obese rats, adipocyte-derived
aldosterone releasing factors lead to hyperaldosteronism.
Hyperaldosteronism results in salt-sensitive hypertension
as well as proteinuria in the obese hypertensive rats. Salt
loading exacerbated the proteinuria and also resulted in
cardiac diastolic dysfunction. Fujita proposed that salt and
aldosterone worked in synergy with the cardiovascular
system through overproduction of oxidative stress. ROS,
induced by adipokines such as tumor necrosis factor-alpha,
nonesteriﬁed fatty acids, angiotensinogen activated the
mineralocorticoid receptor, in an aldosterone-independent
fashion. The hypothesis proposed aldosterone and mineralo-
corticoid receptor activation may play an important role in
the development of salt-sensitive hypertension, as well as the
cardiovascular and renal injury seen in metabolic syndrome.
Fatty acids themselves can mediate relative vasoconstriction
[61].
5. Interventions
5.1. Diet. Some experts debate the clinical utility of aggre-
gating individual risk factors into a speciﬁc diagnosis of
metabolic syndrome when medically each risk factor is
addressedseparately.Atthistime,thereisnosinglemetabolic
syndrome diet recommended. The main strategy has been
to reverse contributory factors such as an atherogenic diet,
obesity, and a sedentary lifestyle [62]. Weight management
andphysicalactivityarerecommendedasﬁrst-linetherapyin
order to delay the progression of symptoms [63]. Epidemio-
logicalevidencesuggestsalowerprevalenceofmetabolicsyn-
dromewithdietarypatternsthatarerichinfruits,vegetables,
whole grains, dairy products, and unsaturated fats. Research
from the dietary approaches to stop hypertension (DASH)
intervention studies demonstrates beneﬁcial eﬀects of an
eating plan rich in low-fat dairy foods, fruits, and vegetables
on blood pressure and lipids. A reduced calorie DASH diet
compared to a control and weight loss diet reduced most of
the metabolic syndrome risks in both men and women and
improved some components beyond that seen in a weight
loss diet [64]. The DASH diet which is rich in calcium,
magnesium, and potassium may also lower the risk of stroke
and hypertension. Fiber and other phytonutrients in fruit
and vegetables may be protective by lowering cholesterol
or markers of inﬂammation. Some studies [65, 66]s u g g e s t
an inverse association between dairy consumption and risk
for metabolic syndrome. In young overweight adults, the
incidence of metabolic syndrome were lower by more than
two-thirdsamongindividualsinthehighestcategoryofdairy
intake (>5 servings per day) compared to lowest category
(<1.5 servings a day) [67]. In addition, a dietary pattern that
had higher intake of low-fat dairy has been associated with a
lower risk of type 2 diabetes in middle aged or older women
and with a 9% lower risk for type 2 diabetes in men [65].
Giugliano et al. explored possible mechanisms underlying a
dietary intervention and randomly assigned 180 patients (99
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aMediterranean-style diet (anincreasein dailyconsumption
of whole grains, vegetables, fruit, nuts, and olive oil) or a
cardiac diet with a decreasedfat intake composed of less than
thirty percent of total calories. Only forty patients in the
intervention group still had metabolic syndrome after two
years compared with seventy-eight patients who consumed
the control diet [68].
Given the increased blood pressure reactivity to dietary
salt in patients with metabolic syndrome, a reduction in
dietary salt may have a beneﬁcial eﬀect on lowering systolic
blood pressure as suggested by Hoﬀman’s study (8.2g/day
to 2.3g/day of salt) [69]. Recently, Chen et al. reported that
metabolic syndrome may enhance blood pressure response
to sodium intake in nondiabetics [70]. However, if low-
sodium diet could lead reduction of metabolic syndrome-
related morbidity and mortality remains to be investigated
in clinical trials.
5.2. Oral Hypoglycemic Agents. In the Diabetes Prevention
Program trial, metformin reduced the risk of diabetes and
the metabolic syndrome in individuals with impaired fasting
glucose and impaired glucose tolerance [71]. The study
examined 3234 nondiabetic persons with elevated fasting
and postload plasma glucose concentrations. Then assigned
participants to metformin (850mg twice daily) or a lifestyle-
modiﬁcation program and followed them for 2.8 years. The
lifestyle intervention reduced the incidence by 58% (95%
CI, 48%–66%) and metformin by 31% (95% C, 17%–43%),
as compared with placebo; the lifestyle intervention was
signiﬁcantly more eﬀective than metformin. In a 10-year
followup of this study, it was found that prevention or
delay of diabetes with lifestyle intervention or metformin
could persist for at least 10 years [72]. In patients with
the metabolic syndrome but normal glucose tolerance, met-
forminhasbeenshowntoimproveendothelialfunction[73].
Unfortunately,metforminiscontraindicatedinpatientswith
chronic kidney disease with reduced GFR. This is due to the
fact that renal clearance of metformin and lactate is reduced,
leading to increased levels of both and possibly causing lactic
acidosis due to a buildup of lactic acid [74].
Thiazolidinediones have also been associated with pro-
tection eﬀects. In the DREAM study, rosiglitazone reduced
the three-year incidence of type 2 diabetes by 60 percent
in patients with impaired glucose tolerance or impaired
fasting glucose who were taking the medication at the time
of testing [75]. The management of insulin resistance with
thiazolidinediones (TZDs) has resulted in greater attention
to activators of the peroxisome proliferator-activated recep-
tors (PPARs). TZDs exert much of their eﬀect on insulin
resistance via activation of PPAR-gamma. TZDs not only
improve glucose control but favorably aﬀect both free fatty
acid metabolism and insulin action. Szapary et al. examined
the eﬀect of pioglitazone in patients with the metabolic
syndrome and demonstrated a signiﬁcant increase in HDL-
Ca n df a v o r a b l ee ﬀects on lipid subfractions without an
eﬀect on triglycerides or low-density lipoprotein cholesterol
(LDL-C) concentrations [76]. Tan et al. [77] noted that
pioglitazone therapy resulted in greater improvements in the
atherogenic index of plasma and lowered triglyceride levels
eﬀectively while achieving greater increases in HDL-C when
compared with rosiglitazone.
5.3. Lipid-Lowering Agents. The eﬃcacy of statins in making
marked reductions in LDL cholesterol, modest reductions
in TG, and small increases in HDL cholesterol is well
documented. ATP III recommended a goal serum LDL
cholesterol of less than 100mg/dL (2.6mmol/L) for sec-
ondary prevention in patients with type 2 diabetes [78,
79]. For this reason the use in patient with metabolic
syndrome has been examined. Patients in the 4S trial who
met the lipid criteria for the metabolic syndrome were
treated with simvastatin, 20 or 40mg/d. It was noted that
they had a 37.5% versus a 36.0% decrease, respectively,
in LDL cholesterol, a 24.1% versus 6.7% decrease in TG,
and a 10.3% versus a 0.6% increase in HDL cholesterol
[80]. Rosuvastatin, 10mg/d administered to patients with
the metabolic syndrome, reduced LDL cholesterol by 47%,
apolipoprotein B by 37%, and TG by 23%, while increasing
HDL cholesterol by 10% [81]. Multiple statins have been
shown to reduce cardiovascular events in patients with and
without CVD, suggesting that this is a class eﬀect of these
drugs. Some of the CVD risk reduction produced by statins
may be attributable to nonlipid pleiotrophic eﬀects of these
drugs [82]. Treatment of patients with known coronary
diseaseandthemetabolicsyndromewithatorvastatin80mg,
compared to atorvastatin 10mg, decreased the rate of major
cardiovascular events at ﬁve years (9.5 versus 13 percent, HR
0.71, 95% CI 0.61–0.84) [79].
In 2009, Robinson et al. [83] evaluated the lipid-lowering
eﬃcacy of ezetimibe/simvastatin 10/20mg versus atorvas-
tatin 10 or 20mg, and ezetimibe/simvastatin 10/40mg
versusatorvastatin 40mg in 1,128 patients withhypercholes-
terolemia and the metabolic syndrome. They noted that
greater improvements in the levels of LDL cholesterol, non-
high-density lipoprotein cholesterol, apolipoprotein B, and
lipid/lipoprotein ratios resulted with ezetimibe/simvastatin
compared with atorvastatin at all speciﬁed dose comparisons
(P<0.001).
5.4. Antihypertensive Therapy. Patients with hypertension
and the metabolic syndrome have high risk of suﬀering
from future cardiovascular and kidney disease. At present
there are no large-scale, randomized trials to establish the
antihypertensive drug of choice for patients with metabolic
syndrome. Most investigators have considered angiotensin-
converting enzyme inhibitors (ACEI) as superior to beta-
blockers and thiazide diuretics [84]. The adverse potential
metabolic side eﬀects of thiazides and beta-blockers on
increase of blood lipids and glucose have led to favoring
of ACEI and calcium channel blockers (CCB) [85]. Beta-
blockers also promote weight gain, and both thiazides and
beta-blockers are associated with an increased incidence of
diabetes, compared to CCB and ACEI [86].
Wright et al. [87] conducted subgroup analysis of the
ALLHAT study reporting that ﬁndings fail to support the
preference for CCBs, alpha-blockers, or ACEIs compared
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syndrome. Wright examined the metabolic and cardiovas-
cular outcomes of the ALLHAT trial in patients stratiﬁed
according to race (black versus nonblack) and the presence
or absence of the metabolic syndrome. Among all the
patients studied, chlorthalidone had the least favorable
eﬀectson blood glucoseandcholesterollevelsthan lisinopril,
amlodipine. In patients without the metabolic syndrome,
both the ACEI and the CCB lowered the incidence of
type 2 diabetes signiﬁcantly, compared to the thiazide [88].
Wright also noted that black patients with the metabolic
syndrome had worse outcomes with lisinopril, compared
to chlorthalidone, with respect to every outcome measured,
likely resulting from a 3–5 mmHg higher systolic pressure
in the black patients on lisinopril, compared to those on
chlorthalidone. Wright concluded that ACEI should not
be the ﬁrst-line monotherapy for black patients with the
metabolic syndrome [87].
5.5. Resistance Training. Over the last decade, physicians
have been examining the eﬀects of resistance training on
metabolic syndrome. Reduced muscle mass as a result of
normal aging and decreased physical activity have been
postulated behind the high prevalence of this disorder.
Improved glycemic control, improved blood lipid proﬁles,
and decreased BP are important for reducing microvascular
and macrovascular complications in people with metabolic
risk. As with increasing adiposity in aging and loss of muscle
mass, the insulin-mediated glucose uptake and TG disposal
in the skeletal muscle of elderly persons is reduced and
the maintenance of a large muscle mass can contribute to
the prevention of type 2 diabetes, which is associated with
cardiovascular disease. Resistance training is contributing to
thedecreaseofmajorriskfactorsforthemetabolicsyndrome
and should be recommended for the management of type
2 diabetes. Although the number of studies on the eﬀects
of resistance training on blood pressure is small, Strasser
conducted meta-analysis conﬁrming that resistance training
does not increase blood pressure as was once thought and
may even have potential beneﬁts on resting systolic blood
pressure [89].
5.6. Surgery. In the prospective controlled clinical study
conducted by Lee et al., metabolic syndrome was prevalent
in 52.2% of morbidly obese individual enrolled. Signiﬁcant
weight reduction 1 year after surgery markedly improved
all aspects of the metabolic syndrome and resulted in a
cure rate of 95.6% [90]. Obesity surgery performed by
laparoscopic surgery is recommended for obese patients
with the metabolic syndrome that have not responded to
conservative measures.
6. Conclusion
Compelling data have indicated that metabolic syndrome
increases the risk of CKD. Experimental studies have sug-
gested that metabolic syndrome may induce CKD via multi-
plemechanicpathways.Whilewearewaitingforrandomized
clinical trial and even new drug development in treating
metabolic syndrome to reduce risk of CKD, current key
strategiesshouldincludepreventionandtreatmentofobesity
and insulin resistance. Lifestyle modiﬁcation particularly
including low sodium diet and increasing physical activity
would be important approaches. Aldosterone antagonists
would also be particular of interest to test in clinical trial
in treating metabolic syndrome to reduce CKD risk. At
the present, early identiﬁcation of metabolic syndrome and
treatment of individual components of metabolic syndrome
mayreducetheriskofCKD.However,theseapproachesneed
be further tested in large randomized clinical trial to verify
their eﬀect on reducing CKD risk.
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